Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials
Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials
复制标题
DOI：
10.1586/14779072.2015.1051034
复制
发表时间：
2015-01-01
影响因子：
2
通讯作者：
Chow, Sheryl L.
中科院分区：
文献类型：
--
作者：
Fajardo, Jeff;Heywood, J. Thomas;Chow, Sheryl L.
奈西立肽是B型利钠肽的重组形式，是一种血管扩张剂，目前推荐作为急性失代偿性心力衰竭（ADHF）患者的添加治疗，这些患者已优化袢利尿剂。随着ADHF住院率的上升，选择适当的治疗方法对于优化疗效和减少不良事件变得更加重要。奈西立肽具有拮抗心力衰竭病理生理过程的许多特性，并且在先前的报告中已经证明了相对的益处;然而，关于其疗效和安全性仍然存在争议。根据最近的临床试验结果，奈西立肽已被证明在目前批准的剂量下是安全的，并强烈认为可用于治疗尽管接受了最佳剂量的静脉袢憩室术但仍有症状的ADHF患者。
Nesiritide, a recombinant form of B-type natriuretic peptide, is a vasodilator and currently recommended as an additive therapy for patients with acute decompensated heart failure (ADHF) who have been optimized on loop diuretics. With hospitalizations for ADHF rising, appropriate selection of therapy becomes even more important to optimize efficacy and reduce adverse events. Nesiritide has many properties that antagonize the pathophysiologic processes of heart failure and has demonstrated a comparative benefit in previous reports; however, controversy still remains with respect to its efficacy and safety. Based on results from recent clinical trials, nesiritide has been shown to be safe at currently approved doses and strongly considered for the treatment of ADHF in patients who remain symptomatic despite optimal doses of intravenous loop divertics.